Senior Director, Corporate Affairs, Communications and Policy Advocacy, France

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Senior Director, Corporate Affairs, Communication and Policy Advocacy will lead the development and execution of oncology-focused Corporate Affairs strategies in France that support the company’s mission of revolutionizing treatment for patients with RAS-addicted cancers. These Corporate Affairs strategies bring together media relations, corporate public affairs, product communications, corporate reputation management and internal communications.

This is an intentionally broad remit, spanning a wide range of disciplines. We are realistic that priorities will need to be set and will evolve over time. We are seeking a versatile leader who approaches this breadth as an opportunity and who understands that the scope of the role reflects the scale of our ambition as a growing business.

Reporting to the VP, Corporate Affairs, Communication and Policy Advocacy, Europe with a strong dotted line to the General Manager, France, this role ensures that the Corporate Affairs strategy is primarily supporting local priorities and market requirements. The strategy should also be aligned with regional and global Corporate Affairs strategies.

• Acts as spokesperson in France, directing enquiries to internal experts as needed.
• Drives proactive media content and strategy around trial results, regulatory milestones, and major oncology congresses (ASCO, ESMO).
• Builds and maintains trusted relationships with top-tier media in France and trade media, ensuring accurate representation of company positions and achievements.
• Monitors media coverage and sentiment, flagging emerging narratives before they require a crisis response.

• Ensures consistent messaging across earned, owned, and shared channels, and aligns spokesperson strategy and media plans with global priorities.

• Owns the country-level corporate reputation strategy for France, ensuring consistency with the global corporate narrative and brand.
• Monitors reputation indicators and stakeholder sentiment, giving leadership early warning of emerging risks and opportunities.
• Leads local crisis and issues management, protecting and enhancing the company's reputation during sensitive events.
• Builds executive visibility and thought leadership within the local business, healthcare, and policy community, positioning leaders as trusted voices on oncology innovation.
• In partnership with the local Value, Market Access and Pricing team, pursues corporate Public Affairs activities, including engagement with government and stakeholder institutions in France on broader company issues.
• Maps and monitors the evolving policy environment in France, including government, institutions, and regulatory bodies, flagging risks and opportunities to the business.

• Partners with the GM, HR, and corporate functions to build a culture of transparency and pride in the company's oncology impact.
• Designs engagement strategies that build genuine commitment and translate strategy into clear priorities employees can act on.
• Aligns internal messaging with external priorities, cascading France policy and access milestones through engaging channels.

• Leads oncology communications strategy in France across disease awareness, launch, and lifecycle, including congress activity (ASCO, ESMO) that translates…